NCT04489511View on ClinicalTrials.gov

Study of STG-001 in Subjects With Stargardt Disease

PHASE2CompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

October 1, 2020

Primary Completion Date

April 24, 2021

Study Completion Date

April 24, 2021

Conditions
Stargardt Disease-1
Interventions
DRUG

STG-001

Dose 1 or Dose 2 of STG-001 will be administered daily for 28 days to compare safety, pharmacokinetics and pharmacodynamics in Stargardt disease subjects.

Trial Locations (5)

15213

UPMC Eye Center, Pittsburgh

32607

Vitreo Retinal Associates, P.A., Gainesville

75231

Retina Foundation of Southwest, Dallas

85020

Associated Retina Consultants, Phoenix

97239

Casey Eye Institute - OHSU, Portland

All Listed Sponsors
lead

Stargazer Pharmaceuticals, Inc.

INDUSTRY

NCT04489511 - Study of STG-001 in Subjects With Stargardt Disease | Biotech Hunter | Biotech Hunter